AtaiBeckley Inc. (ATAI)

Several events have impacted ATAI's stock price in the past six months. The merger with Beckley Psytech Limited was expected to close in the second half of 2025. Positive topline data from the Phase 2b clinical trial of BPL-003 in treatment-resistant depression were reported, and the Phase 3 program is on track for initiation in Q2 2026. Positive topline results from an exploratory Phase 2a trial of EMP-01 in social anxiety disorder were announced in February 2026. In February 2025, the company completed an equity offering with net proceeds of $59.2 million, extending its cash runway into 2027, and in August 2025, the company reported Q2 2025 financial results, with revenues tripling year-over-year. Multiple analyst firms have reiterated or raised their price targets and maintained positive ratings on ATAI. AtaiBeckley is expected to report Q1 2026 results around May 11, 2026.

As a clinical-stage biopharmaceutical company without commercialized products, AtaiBeckley N.V. has no traditional demand seasonality. Demand for its investigational therapies will be driven by the progress and success of its clinical trials and eventual regulatory approvals.

AtaiBeckley N.V. is a clinical-stage biopharmaceutical company focused on transforming mental health treatment through psychedelic medicine and biotechnology. Formed by the combination of Atai Life Sciences and Beckley Psytech Limited in November 2025, the company develops rapid-acting mental health treatments, with a pipeline of psychedelic-based neuroplastogens and related therapeutics. Key product candidates target conditions like treatment-resistant depression, social anxiety disorder, and alcohol use disorder, with assets including BPL-003, VLS-01, EMP-01, RL-007, GRX-917, EGX-121, EGX-A, EGX-B, ELE-101, and KUR-101. The company also has a drug discovery program for novel, non-hallucinogenic 5-HT2AR agonists for TRD.

AtaiBeckley N.V. is headquartered in Amstelveen, Netherlands, with a corporate office in New York, NY, United States. Atai Life Sciences was founded in Berlin, Germany, with operations in the United States and Germany. Clinical trials have been conducted across multiple countries, including the US.

AtaiBeckley's brand reputation appears largely positive, driven by promising clinical trial results and strong analyst confidence. Positive topline data for BPL-003 and EMP-01 have generated optimistic market sentiment, and the strategic combination with Beckley Psytech is seen as a move to solidify its position as a global leader. The company's commitment to participant-informed research was recognized with a Silver Award in the 2026 Patient Participant Index. A setback in January 2023, where a drug candidate failed to meet its primary endpoint, falls outside the requested one-year timeframe.

Major institutional owners of AtaiBeckley N.V. include UBS Group AG, ARK Investment Management LLC, Candriam Luxembourg S.C.A., Marshall Wace, Llp, CenterBook Partners LP, AdvisorShares Investments LLC, Sumitomo Mitsui Trust Holdings, Inc., Price T Rowe Associates Inc /md/, Nikko Asset Management Americas, Inc., and OP Asset Management Ltd, among others. Peter Thiel is a major investor, and Apeiron Investment Group Ltd. holds a significant stake of 15.14%. Cosmo Feilding-Mellen and Florian Olaf Brand are also listed as individual owners.